Citations

Showing 10 of 108081 citations.

Abstract Number ‐ 7: Final Angiographic, Clinical and Thrombus Composition Results of 1000 Patients in the EXCELLENT Registry
Zaidat, Osama O. , Hacke, Werner, Brinjikji, Waleed , Doyle, Karen, Inoa, Violiza , Humphries, William, Woodward, Keith, Bozorgchami, Hormozd, Boor, Stephan , Cohen, José E. , Taqi, Muhammad , Budzik, Ronald F. , Hussain, Shazam, Estrade, Laurent , Puri, Ajit S , Brekenfeld, Caspar , Nogueira, Raul G. , Andersson, Tommy , Yoo, Albert J. , Hanel, Ricardó A. , Jovin, Tudor G. , Fiehler, Jens , De Meyer, Simon F , Liebeskind, David S. , Haussen, Diogo C , Jabbour, Pascal , François, Olivier , Levy, Elad I. , Dashti, Shervin R , Schirmer, Clemens M. , Leacy, Reade De , Chitale, Rohan V , Siddiqui, Adnan H.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | April 25, 2023 | Volume: 3 | Issue: S1 | Pages: No page available

10.1161/svin.03.suppl_1.007 Get It

Introduction EXCELLENT (NCT03685578; Cerenovus) is a large, prospective, international, real‐world registry of endovascular clot removal in acute ischemic stroke (AIS) with EmboTrap as the first line mechanical thrombectomy (MT) device, which included collection and analysis of the retrieved thrombus material. Methods Between September 2018 and March 2021, 1000 “all‐comer” patients were enrolled at 34 global sites (27 US, 5 EU, 1 UK, 1 Israel) and treated according to standard of care at each center (with Embrotrap as first line). The study employed blind endpoint evaluation, including a core imaging lab and an independent 90‐day mRS assessment. Retrieved clot was collected per each MT maneuver from 538 subjects across 26 sites and clot analysis was performed by independent central labs blinded to clinical data. Results mITT population included 998 subjects. Mean age was 69.9±14.18 years (range 18–102), 51.8% (517/998) subjects were female and 9.9% (97/997) had a pre‐stroke mRS 3–5. Baseline NIHSS was 15.6±6.87 (range 0–36); 10.1% (82/815) subjects had a large core (ASPECTS 0–5); 5.8% (57/990) had posterior stroke; 56.3% (523/929) underwent MT ≤ 6hrs of onset and 38.1% (380/998) received IV‐tPA prior to MT. First pass eTICI 2c‐3 was achieved in 38.3% (377/984) and final 2b‐3 in 94.5 % (930/984; median number of passes = 1) of subjects. 90‐day mRS≤2 or ≤pre‐stroke was 46.9% (429/915) and 90‐day all‐cause mortality was 19.0% (175/921). The univariate analysis of clot components showed high red blood cell and low platelet content were significant predictors of good mRS outcome (p < 0.001 and 0.009) and negative predictors of 90‐day mortality (p < 0.001 and 0.017, respectively). Conclusions This large multi‐center, all‐comer cohort reflects the population undergoing thrombectomy today in a real world‐setting. Final angiographic, clinical and thrombus composition results, along with multivariate analysis of predictors of clinical outcomes, will be presented at the time of the conference.
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline
Bixler, Brooke R., Hoffman‐Censits, Jean , Kulkarni, Girish S. , Potretzke, Aaron M. , Smith, Angela B. , Coleman, Jonathan , Clark, Peter E. , Buckley, David , Chang, Sam S. , Chou, Roger , Matin, Surena F. , Pierorazio, Phillip , Psutka, Sarah P. , Raman, Jay D. , Smith, Laura

Mayo Clinic

Journal of Urology | April 25, 2023 | Volume: 209 | Issue: 6 | Pages: 1071-1081

10.1097/ju.0000000000003480 | PMID 37096584 Get It

Clinical Images: Rice bodies in pseudogout
Bansal, Pankaj , Bansal, Pankaj

Mayo Clinic

Arthritis & Rheumatology | April 25, 2023 | Volume: 75 | Issue: 10 | Pages: 1874-1875

10.1002/art.42542 | PMID 37096576 Get It

Female Sexual Dysfunction: A Primer for Primary Care Health Professionals
Thomas, Holly N. , Merriam, Sarah , Kling, Juliana M. , Casas, Rachel S.

Mayo Clinic

MedEdPORTAL | April 25, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11312 | PMID 37113246 Get It

Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta‐analysis
Donaghy, Paul C. , Habich, Annegret , Kane, Joseph , Lewis, Simon J.G. , Pilotto, Andrea , Donaghy, Paul , Lewis, Simon J G , Habich, Annegret , Carrarini, Claudia , Ferreira, Daniel , Aarsland, Dag , Babiloni, Claudio , Bayram, Ece , Thomas, Alan , Bonanni, Laura

Mayo Clinic

Alzheimer's & Dementia | April 25, 2023 | Volume: 19 | Issue: 7 | Pages: 3186-3202

10.1002/alz.13105 | PMID 37096339 Get It

AbstractIntroductionOperationalized research criteria for mild cognitive impairment with Lewy bodies (MCI‐LB) were published in 2020. The aim of this systematic review and meta‐analysis was to review the evidence for the diagnostic clinical features and biomarkers in MCI‐LB set out in the criteria.MethodsMEDLINE, PubMed, and Embase were searched on 9/28/22 for relevant articles. Articles were included if they presented original data reporting the rates of diagnostic features in MCI‐LB.ResultsFifty‐seven articles were included. The meta‐analysis supported the inclusion of the current clinical features in the diagnostic criteria. Evidence for striatal dopaminergic imaging and meta‐iodobenzylguanidine cardiac scintigraphy, though limited, supports their inclusion. Quantitative electroencephalogram (EEG) and fluorodeoxyglucose positron emission tomography (PET) show promise as diagnostic biomarkers.DiscussionThe available evidence largely supports the current diagnostic criteria for MCI‐LB. Further evidence will help refine the diagnostic criteria and understand how best to apply them in clinical practice and research.Highlights A meta‐analysis of the diagnostic features of MCI‐LB was carried out. The four core clinical features were more common in MCI‐LB than MCI‐AD/stable MCI. Neuropsychiatric and autonomic features were also more common in MCI‐LB. More evidence is needed for the proposed biomarkers. FDG‐PET and quantitative EEG show promise as diagnostic biomarkers in MCI‐LB.
National trends in prescription drug expenditures and projections for 2023
Tichy, Eric M. , Hoffman, James M. , Tadrous, Mina , Rim, Matthew H, Suda, Katie J. , Cuéllar, Sandra , Clark, John Spencer , Newell, Mary Kate, Schumock, Glen T.

Mayo Clinic

American Journal of Health-System Pharmacy | April 24, 2023 | Volume: 80 | Issue: 14 | Pages: 899-913

10.1093/ajhp/zxad086 | PMID 37094296 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2023 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2023 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for biosimilars, cancer drugs, diabetes medications, generics, COVID-19 pandemic influence, and specialty drugs. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2023 were based on a combination of quantitative analyses and expert opinion. Results In 2022, overall pharmaceutical expenditures in the US grew 9.4% compared to 2021, for a total of $633.5 billion. Utilization (a 5.9% increase), price (a 1.7% increase) and new drugs (a 1.8% increase) drove this increase. Adalimumab was the top-selling drug in 2022, followed by semaglutide and apixaban. Drug expenditures were $37.2 billion (a 5.9% decrease) and $116.9 billion (a 10.4% increase) in nonfederal hospitals and clinics, respectively. In clinics, new products and increased utilization growth drove growth, with a small impact from price changes. In nonfederal hospitals, a drop in utilization led to a decrease in expenditures, with price changes and new drugs contributing to growth in spending. Several new drugs that will influence spending have been or are expected to be approved in 2023. Specialty and cancer drugs will continue to drive expenditures along with the evolution of the COVID-19 pandemic. Conclusion For 2023, we expect overall prescription drug spending to rise by 6.0% to 8.0%, whereas in clinics and hospitals we anticipate increases of 8.0% to 10.0% and 1.0% to 3.0%, respectively, compared to 2022. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Characteristics of Progressive Multifocal Leukoencephalopathy Associated With Sarcoidosis Without Therapeutic Immune Suppression
Fletcher, Anita, Toledano, Michel , White, Emily , Tan, Chen Sabrina , Mao‐Draayer, Yang , Banks, Samantha A. , Aksamit, Allen J. , Thakur, Kiran T. , Cortese, Irene , Bhattacharyya, Shamik , Bhattacharyya, Shamik , Banks, Samantha , McEntire, Caleb R.S. , Epstein, Samantha E. , Gelfand, Jeffrey M. , Anand, Pria

Mayo Clinic

JAMA Neurology | April 24, 2023 | Volume: 80 | Issue: 6 | Pages: 624

10.1001/jamaneurol.2023.0841 | PMID 37093609 Get It

ImportanceProgressive multifocal leukoencephalopathy can occur in the context of systemic sarcoidosis (S-PML) in the absence of therapeutic immune suppression and can initially be mistaken for neurosarcoidosis or other complications of sarcoidosis. Earlier recognition of S-PML could lead to more effective treatment of the disease.ObjectiveTo describe characteristics of patients with S-PML.Design, Setting, and ParticipantsFor this case series, records from 8 academic medical centers in the United States were reviewed from 2004 to 2022. A systematic review of literature from 1955 to 2022 yielded data for additional patients. Included were patients with S-PML who were not receiving therapeutic immune suppression. The median follow-up time for patients who survived the acute range of illness was 19 months (range, 2-99). Data were analyzed in February 2023.ExposuresSarcoidosis without active therapeutic immune suppression.Main Outcomes and MeasuresClinical, laboratory, and radiographic features of patients with S-PML.ResultsTwenty-one patients with S-PML not receiving therapeutic immune suppression were included in this study, and data for 37 patients were collected from literature review. The median age of the 21 study patients was 56 years (range, 33-72), 4 patients (19%) were female, and 17 (81%) were male. The median age of the literature review patients was 49 years (range, 21-74); 12 of 34 patients (33%) with reported sex were female, and 22 (67%) were male. Nine of 21 study patients (43%) and 18 of 31 literature review patients (58%) had simultaneous presentation of systemic sarcoidosis and PML. Six of 14 study patients (43%) and 11 of 19 literature review patients (58%) had a CD4+ T-cell count greater than 200/μL. In 2 study patients, a systemic flare of sarcoidosis closely preceded S-PML development. Ten of 17 study patients (59%) and 21 of 35 literature review patients (60%) died during the acute phase of illness. No meaningful predictive differences were found between patients who survived S-PML and those who did not.Conclusions and RelevanceIn this case series, patients with sarcoidosis developed PML in the absence of therapeutic immune suppression, and peripheral blood proxies of immune function were often only mildly abnormal. Systemic sarcoidosis flares may rarely herald the onset of S-PML. Clinicians should consider PML in any patient with sarcoidosis and new white matter lesions on brain magnetic resonance imaging.
Neutralizing Monoclonal Antibody Use and COVID-19 Infection Outcomes
Ambrose, Nalini, Anderson, Brian, Barrera-Oro, Julio, Campion, Francis X. , Danan, Risa, D’Arinzo, Lauren , Drews, Ashley, Erlandson, Karl J. , Fitzgerald, Kristin , García, Melissa, Gong, Carlene, Hanna, George J. , Lopansri, Bert K. , Musser, James M. , Piantadosi, Steven , Pritt, Bobbi S. , Roberts, Seth, Sandmeyer, Suzanne , Stein, David , Webb, Brandon , Yttri, Jennifer, O'horo, John, Pritt, Bobbi, Pritt, Bobbi S , Amin, Alpesh , Bertagnolli, Monica M. , Chow, Daniel S. , Gaspar, Fraser W. , Jones, Stephen L. , O’Horo, John C. , Razonable, Raymund R. , Vahidy, Farhaan S

Mayo Clinic

JAMA Network Open | April 24, 2023 | Volume: 6 | Issue: 4 | Pages: e239694

10.1001/jamanetworkopen.2023.9694 | PMID 37093599 Get It

ImportanceEvidence on the effectiveness and safety of COVID-19 therapies across a diverse population with varied risk factors is needed to inform clinical practice.ObjectiveTo assess the safety of neutralizing monoclonal antibodies (nMAbs) for the treatment of COVID-19 and their association with adverse outcomes.Design, Setting, and ParticipantsThis retrospective cohort study included 167 183 patients from a consortium of 4 health care systems based in California, Minnesota, Texas, and Utah. The study included nonhospitalized patients 12 years and older with a positive COVID-19 laboratory test collected between November 9, 2020, and January 31, 2022, who met at least 1 emergency use authorization criterion for risk of a poor outcome.ExposureFour nMAb products (bamlanivimab, bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab) administered in the outpatient setting.Main Outcomes and MeasuresClinical and SARS-CoV-2 genomic sequence data and propensity-adjusted marginal structural models were used to assess the association between treatment with nMAbs and 4 outcomes: all-cause emergency department (ED) visits, hospitalization, death, and a composite of hospitalization or death within 14 days and 30 days of the index date (defined as the date of the first positive COVID-19 test or the date of referral). Patient index dates were categorized into 4 variant epochs: pre-Delta (November 9, 2020, to June 30, 2021), Delta (July 1 to November 30, 2021), Delta and Omicron BA.1 (December 1 to 31, 2021), and Omicron BA.1 (January 1 to 31, 2022).ResultsAmong 167 183 patients, the mean (SD) age was 47.0 (18.5) years; 95 669 patients (57.2%) were female at birth, 139 379 (83.4%) were White, and 138 900 (83.1%) were non-Hispanic. A total of 25 241 patients received treatment with nMAbs. Treatment with nMAbs was associated with lower odds of ED visits within 14 days (odds ratio [OR], 0.76; 95% CI, 0.68-0.85), hospitalization within 14 days (OR, 0.52; 95% CI, 0.45-0.59), and death within 30 days (OR, 0.14; 95% CI, 0.10-0.20). The association between nMAbs and reduced risk of hospitalization was stronger in unvaccinated patients (14-day hospitalization: OR, 0.51; 95% CI, 0.44-0.59), and the associations with hospitalization and death were stronger in immunocompromised patients (hospitalization within 14 days: OR, 0.31 [95% CI, 0.24-0.41]; death within 30 days: OR, 0.13 [95% CI, 0.06-0.27]). The strength of associations of nMAbs increased incrementally among patients with a greater probability of poor outcomes; for example, the ORs for hospitalization within 14 days were 0.58 (95% CI, 0.48-0.72) among those in the third (moderate) risk stratum and 0.41 (95% CI, 0.32-0.53) among those in the fifth (highest) risk stratum. The association of nMAb treatment with reduced risk of hospitalizations within 14 days was strongest during the Delta variant epoch (OR, 0.37; 95% CI, 0.31-0.43) but not during the Omicron BA.1 epoch (OR, 1.29; 95% CI, 0.68-2.47). These findings were corroborated in the subset of patients with viral genomic data. Treatment with nMAbs was associated with a significant mortality benefit in all variant epochs (pre-Delta: OR, 0.16 [95% CI, 0.08-0.33]; Delta: OR, 0.14 [95% CI, 0.09-0.22]; Delta and Omicron BA.1: OR, 0.10 [95% CI, 0.03-0.35]; and Omicron BA.1: OR, 0.13 [95% CI, 0.02-0.93]). Potential adverse drug events were identified in 38 treated patients (0.2%).Conclusions and RelevanceIn this study, nMAb treatment for COVID-19 was safe and associated with reductions in ED visits, hospitalization, and death, although it was not associated with reduced risk of hospitalization during the Omicron BA.1 epoch. These findings suggest that targeted risk stratification strategies may help optimize future nMAb treatment decisions.
Trends in race and sex reporting in lung cancer phase III clinical trials
Aslam, Faaiq , Lou, Yanyan , Colón‐Otero, Gerardo , Sher, Taimur , Aslam, Faaiq N , Manochakian, Rami

Mayo Clinic

No container title available | April 24, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.168236462.28807061/v1 Get It

Background: To understand the changing trends in reporting of race and sex as a demographic variable in phase III lung cancer clinical trials published over the last 35 years. Methods: A total of 426 articles reporting results of phase 3 lung cancer clinical trials published from 1984 to 2019 were identified in PubMed. Statistical analysis on trends over time on percentage of minority and female participation were performed. Results: Only 137 (32.2%) of the 426 studies analyzed reported race of participants. Among those studies, we found that the mean participation rate of white participants was significantly higher (82.65%) (p < 0.001). We found a decrease in African American participants and an increase in Asian participants over time. When looking at sex, we found that although the rate of male participation (69.02%) was significantly higher than that of female participation (30.98%), the female participation has improved with time at a rate of 0.65% per year. Conclusions: We found that the reporting and participation of minority races continues to lag that of other demographic factors like sex in phase III clinical trials in lung cancer. Especially in African Americans, where the participation in lung cancer phase III clinical trials has declined despite the rising incidence in lung cancer.
Faculty Opinions recommendation of Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021.
Gersh, Bernard J.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | April 24, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.742400313.793598381 Get It